0001171843-26-002568
SEC filingA breakout year marked by a shift to profitability, driven by a strategic pivot toward system sales and strong U.S. commercial execution. The company leveraged its expanded FDA clearances and robust cash position to deliver record revenue and its first full-year profit.
The fiscal year represents a defining period for BrainsWay, characterized by a decisive strategic pivot toward a sales-oriented business model. Management has emphasized the Sale Model, wherein the Deep TMS system is sold to the customer for a fixed purchase price. This shift fundamentally alters the company's revenue recognition profile, with control transferring to the customer upon delivery. Consequently, the cost of revenues structure has evolved to include a significant component for the Deep TMS systems sold, reflecting the direct costs associated with this higher-velocity sales approach. While this model introduces variability in cost of revenues, management expects these costs to increase in absolute dollars only to the extent that revenues increase, maintaining a disciplined correlation between top-line growth and expense management.
The company's operational signals highlight the clinical differentiation underpinning its commercial strategy. BrainsWay’s H1 Coil technology demonstrates a capacity for total stimulated brain volume of 17 cm3, a substantial technical advantage compared to the 3 cm3 capacity of traditional figure-8 coils. This technological depth supports the company's ability to secure and leverage expanded FDA clearances, driving adoption in key markets. The strategic decision to maintain ownership of systems placed under alternative models allows BrainsWay to preserve a relatively low cost of revenues for those specific units, creating a hybrid operational structure that balances immediate revenue realization through sales with long-term asset retention.
BrainsWay enters the upcoming fiscal period with a fortified balance sheet. Management has expressed confidence that existing cash resources are sufficient to fund operating expenses and capital expenditure requirements for the foreseeable future. This liquidity position provides strategic flexibility, allowing the company to focus on commercial execution without the immediate pressure of external financing. The outlook remains focused on scaling U.S. operations, with an anticipation that expenses will increasingly be incurred in U.S. dollars as the operational footprint expands, while a portion of personnel expenses in Israel continues to be denominated in NIS. This financial stability underpins the company's ability to sustain its pivot toward a sales-driven model while navigating the currency dynamics inherent in its global operations.